Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients

Acta Oncologica

Volumn 47, Issue 1, 2008, Pages 104-109

  Loven, David ^a   Be'ery, Einat ^b   Yerushalmi, Rinat ^b   Koren, Claude ^b   Sulkes, Aaron ^b   Lavi, Idit ^c   Shaked, Yuval ^d   Fenig, Eyal ^b  

^a HAEMEK MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c CARMEL MEDICAL CENTER   (Israel)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL ARTICLE; HUMAN; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECTUM CARCINOMA; THROMBOCYTE COUNT;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PELVIS; PLATELET-DERIVED GROWTH FACTOR; RECTAL NEOPLASMS; STATISTICS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37549060729     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701472470     Document Type: Article

References (22)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwrigt T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
3. Garcia AA, Oza AM, Hirte H, Fleming G, Tsao-Wei D, Roman L, et al. Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent avarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. J Clin Oncol 2005;23;455s Abstract 5000.
4. Lissoni P, Fugamalli E, Malugani F, Ardizzoia A, Secondino S, Tancini G, et al. Chemotherapy and angiogenesis in advanced cancer: Vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer. Int J Biol Markers 2000;15:308-11.
5. Mahaseth H, Dudek AZ. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: Correlation with treatment response and survival. Cancer Invest 2005;23:193-200.
6. Pedersen LM, Klausen TW, Davidsen UH, Johnsen HE. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol 2005;84:510-6.
7. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-8.
8. Ria R, Portaluri M, Russo F, Cirulli T, Di Pietro G, Bambace S, et al. Serum levels of angiogenic cytokines decrease after antineoplastic radiotherapy. Cancer Lett 2004;216:103-7.
9. McDonnell CO, Harmey JH, Bouchier-Hayes DJ, Walsh TN. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer. Br J Surg 2001;88:1105-9.
10. Druzgal CH, Chen Z, Yeh NT, Thomas GR, Ondrey FG, Duffey DC, et al. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head Neck 2005;27:771-84.
11. Dvorak HF. Vascular Permeability Factor/ Vascular Endothelial Growth Factor: A critical cytokine of tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
12. Sundberg C, Ljungstrom M, Lindmark G, Gerdin B, Rubin K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol 1993;143:1377-88.
13. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
14. Yerushalmi R, Idelevich E, Dror Y, Stemmer SM, Figer A, Sulkes A, et al. Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-Fluorouracil (5-FU). J Surg Oncol 2006;93:529-33.
15. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: Correlation with treatment response and survival. Cancer Invest 2005;23:193-200.
16. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole' F, et al. A Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002;13:73-80.
17. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, et al. Platelet: Transporter of vascular endothelial growth factor. Clin Cancer Res 1997;32:187-90.
18. Salgado R, Benoy I, Bogers J, Weitjens R, Vermeulen P, Dirix L, et al. Platelets and vascular endothelial growth factor (VEGF): A morphological and functional study. Angiogenesis 2001;4:37-43.
19. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: Implications for wound healing. Plast Reconstr Surg 2004;114:1502-8.
20. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: Clinical evidence of platelet scavenging? Clin Cancer Res 2000;6:3147-52.
21. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003;100:12917-22.
22. Damber JE, Valbo C, Albertsson P, Lennernas B, Norrby K. The antitumor effect of low-dose continuous chemotherapy may partly be mediated by throbospondin. Cancer Chemother Pharmacol 2005;7:1-7.